Amal Al-Azmi\*, Mickey Vinodh

Dept. of Chemistry, Kuwait University P. O. Box 5969, Safat 13060, Kuwait \*Corresponding author: amalrchem@gmail.com

#### Abstract

Cyclisation of 5-amino-1-(4-nitrophenyl)-1H-1,2,3-triazole-4-carbimidoyl cyanide and 3amino-3-((Z)-2-cyano-2-phenylvinylamino)maleonitrile using either triethyl orthoformate or triethyl orthopropionate in dimethylformamide (DMF):1,4-dioxane (1:1 v/v) mixture under reflux conditions afforded 5-alkyl-3-(4-nitrophenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-7and (*Z*)-1-(2-cyano-2-phenylvinyl)-2-alkyl-1*H*-imidazole-4,5-dicarbonitriles, carbonitriles respectively, in moderate to good yields. The structures of these novel compounds were confirmed with <sup>1</sup>H/<sup>13</sup>C nuclear magnetic resonance (NMR), infrared spectroscopy (IR), and high-resolution mass spectroscopic methods. Two representative compounds from these 5-ethyl-3-(4-nitrophenyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-7molecules. namely carbonitrile and (Z)-1-(2-cyano-2-phenylvinyl)-1H-imidazole-4,5-dicarbonitrile, were further analysed by the single-crystal X-ray diffraction method. A comprehensive study of structural features and intermolecular interactions present among these heterocyclic compounds was carried out. The crystal data were further examined by a Hirshfeld surface analysis, which provided qualitative and quantitative information on various intermolecular interactions experienced within the crystal network.

Keywords: Crystal structure; hirshfeld surface analysis; imidazole; pyrimidine; triazole.

## 1. Introduction

Cyclisation reactions in synthetic heterocyclic chemistry are one of the most useful reactions that lead to different types of heterocyclic compounds, especially N-heterocyclic rings. Among the reagents used in these cyclisations, triethyl orthoalkylates (orthoesters) **1a-c** 

RC(OEt)<sub>3</sub> are particularly significant (Woodward, 1950, Johnson, 1991, Alves *et al.*, 1990; Booth *et al.*, 1992; Al-Azmi *et al.*, 2003; Al-Azmi, 2015; Al-Azmi *et al.*, 2001; Al-Azmi & Kumari, 2009; Al-Azmi, 2005; Al-Azmi & Kalarikkal, 2013; Al-Azmi, 2020; Al-Azmi & Mahmoud, 2020) as they increase the ring by a carbon atom and the substituents on the carbon can be easily controlled by the right choice of an ortho-alkylate derivative. (Woodward, 1950; Johnson, 1991; Alves et al., 1990; Booth et al., 1992; Al-Azmi et al., 2003; Al-Azmi, 2015; Al-Azmi et al., 2001; Al-Azmi & Kumari, 2009; Al-Azmi, 2005, Al-Azmi & Kalarikkal; 2013, Al-Azmi, 2020; Al-Azmi & Mahmoud, 2020). The usual scenario in these types of cyclisation reactions is the attack of a nucleophile, mostly nitrogen, on the electrophilic ortho-alkylate carbon, causing the loss of two ethoxy groups as ethanol molecules. Consequently, this creates a highly electrophilic imidate carbon center that is susceptible to attack by nucleophiles.

-2-

$$OC_{2}H_{5}$$

$$C_{2}H_{5}O_{R}OC_{2}H_{5}$$

$$I$$

$$R a = H$$

$$b = CH_{3}$$

$$c = C_{2}H_{5}$$

In the last decades, triethyl orthoalkylates (orthoesters) have been broadly used by researchers worldwide, including our group, to synthesise many N-heterocycles, especially five- and six-membered rings that have various crucial applications. (Al-Azmi *et al.*, 2003; Al-Azmi, 2015; Al-Azmi *et al.*, 2001; Al-Azmi & Kumari, 2009; Al-Azmi, 2005; Al-Azmi & Kalarikkal, 2013; Al-Azmi, 2020; Al-Azmi & Mahmoud, 2020)

For the synthesis of N-heterocyclic rings, the utility of inexpensive and readily available triethyl orthoalkylates **1** is advantageous, as was demonstrated many times by our group. (Al-Azmi *et al.*, 2003; Al-Azmi, 2015; Al-Azmi *et al.*, 2001; Al-Azmi & Kumari, 2009; Al-Azmi, 2005; Al-Azmi & Kalarikkal, 2013; Al-Azmi, 2020; Al-Azmi & Mahmoud, 2020) The most exciting building block produced from triethyl orthoalkylates **1a** is (*Z*)-ethyl-(*N*)-[2-amino1,2-dicyanovinyl]formimidate **3** (commonly known as monoimidate), which can be prepared for excellent yield (80–90%) by refluxing a mixture of

equimolar amounts of diaminomaleontrile (DAMN) 2 and triethyl orthoformate 1a in 1,4-dioxane. (Woodward, 1950, Johnson, 1991) Monoimidate 3 normally reacts with a wide range of primary amines in the presence of a catalytic amount of anilinium hydrochloride to avert decomposition and to produce  $(Z)-N^1-(4-aryl)-N^2-[2-amino1,2$ dicyanovinyl]formamidines 4. (Woodward, 1950, Johnson, 1991; Alves et al., 1990; Booth et al., 1992; Al-Azmi et al., 2003) Formamidine derivatives **4** are also reported to be excellent building blocks for several N-heterocycles, including imidazoles, purines, triazoles, pyrroles, and pyrimidines. (Alves et al., 1990; Booth et al., 1992; Al-Azmi et al., 2003; Al-Azmi, 2015; Yildirim et al., 2002) These compounds display fascinating applications, such as pharmaceutical, medicinal, and anticorrosive. (Al-Azmi et al., 2003; Al-Azmi, 2015)

This prompts us to employ both 5amino-1-(4-nitrophenyl)-1H-1,2,3-triazole-4-carbimidoyl cyanide, which has been prepared previously by our group (Al-Azmi & Kalarikkal, 2013), and the



readily available 2-phenyl-3oxopropanenitrile reagent (Al-Azmi & Kalarikkal, 2017) to synthesise new Nheterocyclic compounds by utilising their reaction with orthoesters **1**. To the best of our knowledge, this rather obvious approach has not been explored before.

In the present paper, we report the synthesis of new 5-alkyl-3-(4-nitrophenyl)-3H-[1,2,3]triazolo[4,5-d] pyrimidine-7-carbonitriles and (Z)-1-(2-cyano-2-phenylvinyl)-2-alkyl-1H-imidazole-4, 5-dicarbonitriles. The characterisation of these newly synthesised compounds, along with a detailed single-crystal X-ray diffraction analysis of two representative samples among them, is also presented and discussed.

## 2. Results and Discussion

2.1 Synthesis of Triazolopyrimidine and Imidazole dicarbonitrile Derivatives

The precursor molecule used for the synthesis of triazolopyrimidine compounds

discussed in this work is 5-amino-1-(4-nitrophenyl)-1*H*-1,2,3-triazole-4-

carbimidoyl cyanide **5**. This nitrophenyl derivative **5** is prepared after cyclisation of 2-(5-amino-1-(4-nitrophenyl)-1*H*-1,2,3-

(triazol-4-yl)-2-iminoacetonitrile using a mixture of ethanol and a catalytic amount 1,8-diazabicyclo[5.4.0]undec-7-ene of (DBU), as described in the literature. (Al-Azmi & Kalarikkal, 2013). The 4nitrophenyl derivative 5 was used because it does not produce a mixture of the triazole-4-carbimidoyl cyanide and triazole-2-oxoacetonitrile, as 4do methoxyphenyl, phenyl, 4-chlorophenyl, or 4-tolyl substituents. The synthesis of triazolopyrimidine derivatives (**6a** and **6b**) was carried out by refluxing triazole 5 with an excess of triethyl orthoformate 1a or triethyl orthopropionate 1c in a DMF:1,4dioxane solvent mixture (1:1 v/v) for six hours, as depicted in Scheme 1. (Al-Azmi & Kumari, 2009) The details about the reaction workup and product purification are provided in the experimental section.



Scheme 1: Synthesis of triazolopyrimidine derivatives 6a and 6b

The <sup>1</sup>H NMR spectrum indicated the disappearance of both (NH) and NH<sub>2</sub> functions, and instead, both C<u>H</u> and C<sub>2</sub>H<sub>5</sub> signals were detected at  $\delta$  9.41 parts per million (ppm),  $\delta$  1.38, and  $\delta$  2.94 ppm for **6a** and **6b**, respectively.

The Schiff base 3-amino-3-((Z)-2cyano-2-phenylvinylamino)maleonitrile **8**, which is the precursor molecule for imidazole-4,5-dicarbonitriles **9a,b**, was prepared by reacting 2-phenyl-3oxopropanitrile **7** with diaminomaleonitrile (DAMN) **2** in acetic acid, and the mixture was stirred for 24 hours at room -4-

temperature. The reaction provided the intended product as a green powder in good yield. The Schiff base structure was confirmed by the presence of three cyano functions in the infrared radiation (IR) and <sup>13</sup>C NMR spectra, while the <sup>1</sup>H NMR spectra indicated the presence of both NH and NH<sub>2</sub> proton signals.

Imidazole-4,5-dicarbonitriles **9a,b** were synthesised by reacting **8** with an excess of triethyl orthoformate **1a** or propionate **1c** under reflux conditions in the presence of a mixture of 1:1 DMF:1,4-dioxane for about six hours (Scheme 2). It is found that **9a**  and **9b** are produced in 67% and 65% yields, respectively. The cyclisation was achieved when the <sup>1</sup>H NMR spectra of **9a** revealed the presence of hydrogen (C<u>H</u>) at  $\delta$  8.89 ppm, and **9b** CH<sub>2</sub>CH<sub>3</sub> protons appeared at  $\delta$  1.21 ppm and  $\delta$  2.84 ppm.

Al-Azmi described the preparation of 2-alkylimidazole-4,5-dicarbonitrile derivatives when (Z)- $N^1$ -aryl- $N^2$ -(2-amino-1,2-dicyanovinyl) formamidines were refluxed with triethyl orthoacetate **1b** or propionate **1c**. (Al-Azmi & Kumari, 2009)



Scheme 2: Synthesis of imdazole derivatives 9a and 9b.

2.2 Single - Crystal X - Ray Diffraction Studies

Triazolopyrimidines occupy a vital place in the pharmaceutical field. They have been reported to act as angiotensin II receptor antagonists. (Nicolai et al., 1994) It is also illustrated that derivatives of the triazolopyrimidine species, such as [1,2,4-oxadiazolyl]methyl-3*H*-[1,2,3]triazo lo[4,5-d]pyrimidine, exhibit moderate to high antimicrobial activity. (El-Sayed et al., 2012) Moreover, a series of 1,2,4triazolopyrimidines were prepared and evaluated as antitumor agents using a **DNA-binding** assay on thin-layer chromatography (TLC) plates. (Hassan et 2017) The 4,5-dicyanoimidazole al.. analogues, on the other hand, have been reported as potential anticancer (Ali et al., and additionally, 2017), they were involved in applications as photo-redox push-pull their catalysts due to characteristics. (Plaquet et al., 2011, Hloušková & Bureš, 2017) Based on all these encouraging results, it is expected that the newly synthesised compounds reported in this work can have impressive applications in the pharmaceutical industry.

Before investigating the pharmaceutical applications, it is necessary to have a complete idea about the structural details with respect to the compound of interest. The bonding nature of the species, especially the presence of any supramolecular non-bonding interactions possible among such molecules, should also be investigated in detail. Such structural and non-bonding interaction studies provide an idea about the nature of

the molecule and its affinity/reactivity toward target molecules in biomedical reactions. Thus, it is helpful to design suitable molecules for certain medicinal actions. A single-crystal X-ray diffraction analysis is considered the best method for such structural and interaction studies if the compound of interest is solid in nature and crystalline. Therefore, due to an interest in the pharmaceutical applications of triazolopyrimidines and imidazole-4,5dicarbonitriles, we carried out a detailed crystal structure analysis of two samples (**6b** 9a) representative and synthesised in the present work.

2.3 Structural Characterisations of Triazolopyrimidine **6b** and Imidazole dicarbonitrile **9a** by Single-Crystal X-Ray Diffraction

The crystal structures of triazolopyrimidine **6**b and imidazole dicarbonitrile **9a** are given in Figure 1, and their corresponding crystallographic data are provided in Table 1. The crystal data shows that both these molecules are not planar (Figure 2). The plane of nitrophenyl moiety of **6b** is twisted from the triazolopyrimidine plane by about 15°. At the same time, the distortion of planarity in imidazole dicarbonitrile is more pronounced in its crystal structure. It is found that the bridging nitrile spacer between the two aromatic moieties is oriented to a different plane. The nitrile spacer is twisted 32° from the substituted imidazole plane and about 27° from the other phenyl fragment plane.



**Fig. 1.** Crystal structure (thermal ellipsoid representation; 50% probability) of 5-ethyl-3-(4-nitrophenyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidine-7-carbonitrile **6b** and (*Z*)-1-(2-cyano-2-phenylvinyl)-1*H*-imidazole-4,5-dicarbonitrile **9a**.



Fig. 2. Crystal structure of 6b and 9a showing the distortion from planarity.

| Crystal sample  | 6b                                  | 9a                                     |  |  |
|---|-------------------------------------|--|--|--|
| Chemical formula  | $C_{13}H_9N_7O_2$                   | $C_{14}H_7N_5$                         |  |  |
| $M_{ m r}$  | 295.26                              | 245.24                                 |  |  |
| Crystal system, space group   | Monoclinic, $P2_1/n$                | Monoclinic, $C2/c$                     |  |  |
| Temperature (K)   | 293                                 | 150                                    |  |  |
| <i>a</i> , <i>b</i> , <i>c</i> (Å)  | 10.300 (3), 8.923 (3), 14.672 (4)   | 14.3602 (16), 6.9255 (8)<br>25.895 (3) |  |  |
| β (°)   | 90.761 (7)                          | 104.482 (8)                            |  |  |
| $V(Å^3)$  | 1348.3 (6)                          | 2493.5 (5)                             |  |  |
| Ζ   | 4                                   | 8                                      |  |  |
| Radiation type  | Μο Κα                               | Μο <i>Κ</i> α                          |  |  |
| $\mu (mm^{-1})$   | 0.11                                | 0.09                                   |  |  |
| Crystal size (mm)   | $0.20\times0.15\times0.10$          | $0.25 \times 0.20 \times 0.15$         |  |  |
| Diffractometer  | Rigaku R-AXIS RAPID                 | Rigaku R-AXIS RAPID                    |  |  |
| Absorption correction   | Multi-scan<br>ABSCOR (Rigaku, 1995) | Multi-scan<br>ABSCOR (Rigaku, 1995)    |  |  |
| $T_{\min}, T_{\max}$  | 0.637, 0.989                        | 0.559, 0.987                           |  |  |
| Numberofmeasured,independentandobserved $[I>$ $2\sigma(I)$ reflections            | 8548, 2689, 1082                    | 9679, 2277, 1846                       |  |  |
| $R_{\rm int}$   | 0.064                               | 0.027                                  |  |  |
| $(\sin \theta / \lambda)_{max} (\text{\AA}^{-1})$                                 | 0.625                               | 0.602                                  |  |  |
| $R[F^2 > 2\sigma(F^2)], wR(F^2), S$   | 0.043, 0.129, 0.84                  | 0.037, 0.111, 1.10                     |  |  |
| Number of reflections   | 2689                                | 2277                                   |  |  |
| Number of parameters  | 200                                 | 172                                    |  |  |
| H-atom treatment  | Constrained                         | Constrained                            |  |  |
| $\Delta \rho_{\text{max}}, \Delta \rho_{\text{min}} (e \text{ Å}^{-3})$           | 0.17, -0.17                         | 0.13, -0.15                            |  |  |
| 2.4 Non-Bonding Interactions Within 6h crystals of both 6h and 0a. In the case of |                                     |  |  |  |

Table 1. Experimental details and crystal data for compounds 6b and 9a.

2.4 Non-Bonding Interactions Within **6b** and **9a** Crystals

Both triazolopyrimidine **6b** and imidazole dicarbonitrile **9a** possess heterocyclic rings and terminal nitrogen or oxygen containing functional groups. This enables these molecules to engage efficient H-bonding/non-bonding interactions with their adjacent counterparts. Multiple H-bonding interactions are observed in the

crystals of both **6b** and **9a**. In the case of triazolopyrimidine, most intermolecular supramolecular bonds are through C-H...N, C-H...C and C-H...O type interactions, whereas, for imidazole dicarbonitrile **9a**, such bonds are mainly through C-H...N interactions. The H-bonding/non-bonding observed among **6b**, and **9a** are depicted in Figure 3 and Figure 4, respectively, and their quantitative details are given in Table 2.



**Fig. 3.** H-bonding/non-bonding interactions in **6b** crystals. C-H---O, C-H---N and C-H---C interactions are represented by red, blue and green dotted lines, respectively (symmetry code: (<sup>i</sup>) 1/2-x, 1/2+y, 1/2-z; (<sup>ii</sup>) x, -1+y, z; (<sup>iii</sup>) 1/2-x, 1/2+y, 1.5-z; (<sup>iv</sup>) 1/2-x, -1/2+y, 1/2-z; (<sup>v</sup>) x, 1+y, z; (<sup>vi</sup>) 1/2-x, -1/2+y, 1.5-z).



**Fig. 4.** H- bonding interactions in **9a** crystals (symmetry code: (<sup>i</sup>) 1/2-x, 1/2-y, 1-z; (<sup>ii</sup>) 1+x, y, z; (<sup>iii</sup>) 1-x, y, 1.5-z; (<sup>iv</sup>) -1+x, y, z).

**Table 2.** Quantitative details of H-binding/non-bonding interactions among **6b** and **9a** crystals (symmetry codes: (<sup>i</sup>) 1/2-x, 1/2+y, 1/2-z; (<sup>ii</sup>) x, -1+y, z; (<sup>iii</sup>) 1/2-x, 1/2+y, 1.5-z); (<sup>i</sup>) 1/2-x, 1/2-y, 1-z; (<sup>ii</sup>) 1+x, y, z; (<sup>iii</sup>) 1-x, y, 1.5-z).

| D-HA                                       | D-H   | HA    | DA       | D-HA   |  |
|--|-------|-------|----------|--------|--|
|  |       |       |          |        |  |
| Triazolopyrimidine 6b                      |       |       |          |        |  |
| C3 <sup>i</sup> -H3 <sup>i</sup> O1        | 0.931 | 2.733 | 3.282(3) | 118.6  |  |
| C6 <sup>ii</sup> -H6 <sup>ii</sup> N3      | 0.930 | 2.657 | 3.571(4) | 167.45 |  |
| C12 <sup>ii</sup> -H12A <sup>ii</sup> N7   | 0.970 | 2.756 | 3.620(4) | 148.7  |  |
| C13 <sup>iii</sup> -H13B <sup>iii</sup> C6 | 0.961 | 2.898 | 3.774(5) | 152.2  |  |
| Imidazole dicarbonitrile 9a                |       |       |          |        |  |
| $C2^{i}-H2^{i}N5$                          | 0.951 | 2.715 | 3.509(2) | 141.48 |  |
| C8 <sup>i</sup> -H8 <sup>i</sup> N5        | 0.950 | 2.565 | 3.508(2) | 171.73 |  |
| C4 <sup>ii</sup> -H4 <sup>ii</sup> N4      | 0.950 | 2.519 | 3.332(2) | 143.6  |  |
| C9 <sup>iii</sup> -H9 <sup>iii</sup> N2    | 0.950 | 2.537 | 3.096(2) | 117.78 |  |

Due to their ability to engage multiple H-bonding/non-bonding interactions, both 6b and 9a are supramolecularly attached to many neighbouring molecules. It is shown that each triazolopyrimidine molecule **6b** is non-covalently bonded with its six neighbouring counterparts and that each imidazole dicarbonitrile 9a is bonded with four neighbours. Also, in the case of the triazolopyrimidine crystal, each molecule interacts with its nearest molecule by  $\pi$ - $\pi$ interaction, which is demonstrated in the information. This supporting π-π interaction is achieved by the face-to-face attachment of two nitrophenyl fragments of **6b** molecules, which are oriented opposite each other.

# 2.5 Hirshfeld Surface Analysis of **6b** and **9a** Crystals

The Hirshfeld surfaces and the related twodimensional (2D) fingerprint plots provide both qualitative and quantitative information about various intermolecular interactions experienced by a species in the crystal. The three-dimensional (3D) dnorm surface is useful to analyse and visualise the intermolecular interactions, and the 2D fingerprint plots offer a quantitative summarisation of the nature and type of various intermolecular contacts experienced by the molecules in the crystal network. (Spackman & Jayatilaka, 2009, McKinnon et al., 2004; McKinnon et al., 2007). The Hirshfeld surface, mapped with a dnorm function for triazolopyrimidine **6b** and imidazole dicarbonitrile 9a molecules in their crystals, is shown in Figure 5, and the corresponding 2D finger plots are given in the supporting information. It should be noted that the red-coloured regions on the dnorm surface represent the intermolecular contacts closer than the sum of the Van der Waals radii, the white colour shows intermolecular distances close to van der Waals contacts with the dnorm equal to zero, and the blue region represents the longer contacts.

-10-



Fig. 5. The Hirshfeld surface mapped with dnorms of **6b** and **9a** when viewing from two different directions.

The red-dominated spots in the Hirshfeld surface of **6b** and **9a** are obviously the strong non-bonding interactions experienced in these systems most of them are the H-bonding type already indicated in Figure 3 and Figure 4. There are also many white shades on the hydrosulphide (HS) surface, indicating additional moderately strong intermolecular contacts within the molecules in these crystals. The 2D fingerprint plots of triazolopyrimidine 6b crystals show that the N...H interactions are the most significant interatomic interactions experienced by this molecule, with a considerable contribution of 29.8%. The C...H and O...H interactions are also in significant this system, with contributions of 18.3% and 15.0%. respectively. Other significant intermolecular interactions in this crystal are H...H (13.3%), N...C (5.9%), C...O (5.3%), N...O (5.0%) and N...N (4.7%). Other possible intermolecular contacts, such as C...C and O...O, are too low to count. In the case of imidazole

dicarbonitrile **9a**, the 2D fingerprint shows that the N...H interactions are the most significant interatomic interactions, with a massive contribution of 45.8%. The C...C interaction is the second-highest significant interaction in this crystal, with a contribution of 16.4%, followed by the H...H interaction (14.9%) and the C...N interaction (10.0%). The contributions of other interactions are C...H (7.8 %) and N...N (5.1%).In short. excellent information about various interatomic interactions experienced by both 6b and 9a molecules within their crystals are obtained from the HS analysis.

# 2.6 Supramolecular Packing of **6b** and **9a** Crystals

As a result of multiple H-bonding/noninteractions. bonding the triazolopyrimidine 6b imidazole and dicarbonitrile **9a** molecules formed a supramolecular network within their crystals with an interesting pattern. The packing pattern of these molecules in their crystals is depicted in Figure 6.



Imidazole dicarbonitrile

Fig. 6. Packing pattern of triazolopyrimidine 6b and imidazole dicarbonitrile 9a molecules in their crystal network.

From its packing pattern, it is evident that the triazolopyrimidine molecule formed twisted one-dimensional polymers in the network, which is interesting in relation to various opto-electronic applications. On the other hand, the packing of imidazole dicarbonitrile 9a molecules, a herringbone type assembly with oppositely oriented 9a sets, is done in a zig-zag manner. The bridging nitrile spacer's orientation to a different plane against the aromatic planes in this molecule makes these packing patterns interesting. The packing features of both these molecules when viewing along

different crystallographic directions are depicted in the supporting information.

#### 3. Conclusion

We have demonstrated a simple and efficient method for cyclisation reactions using orthoesters to obtain pyrimidine and 4,5-dicyanoimidazole derivatives. With these economical and available reagents, the ability to introduce alkyl groups as substituents proved to be effective and productive. The obtained results are straightforward, and they play a valuable part in the synthesis of a series of nitrogen heterocyclic compounds, which are applicable in a group of different research/industrial areas. The single-crystal X-ray diffraction studies provide more insights into the structural aspects of these existence novel compounds; the of multiple supramolecular nonbonding interactions among these compounds suggest them to be very interesting species as functional materials – for example, pharmaceuticals. Application studies based on these novel heterocyclic compounds are being carried out in our lab.

## 4. Experimental

## 4.1 Material and methods

Infrared spectra were recorded using a Jasco FT-IR 6300 instrument. <sup>1</sup>H and <sup>13</sup>C NMR spectra were evaluated with a Bruker DPX instrument at 400/600 megahertz (MHz) for <sup>1</sup>H NMR and 100 MHz for <sup>13</sup>C NMR and dimethyl sulfoxide (DMSO)-d<sub>6</sub> as a solvent, with tetramethyl silane (TMS) as an internal standard. Chemical shifts were reported in parts per million. Mass spectra were measured using a GCeMS DFS Thermo spectrometer in electronic ionisation (EI) (70 electron volts [eV]) mode. Elemental analyses were performed using an Elementar Vario MICRO Cube Melting points were determined by using a Gallenkamp melting point apparatus and were uncorrected. The single-crystal X-ray diffraction analysis was made on a Rigaku R-AXIS RAPID diffractometer. The triazole was prepared following the previously reported procedure. (Al-Azmi and Kalarikkal, 2013).

4.2 Single-crystal data collection and structure refinement

Single crystals of triazolopyrimidine **6b** and imidazole dicarbonitrile **9a** were grown from hot ethanol and hot DCM, respectively (25.0 mg dissolved in 1.00 ml solvent) by slow solvent evaporation. Crystals suitable for diffraction analysis were obtained in one week. The singlecrystal data analysis was made by a R- AXIS RAPID II Rigaku diffractometer using filtered Mo-K $\alpha$  radiation. While the data collection from triazolopyrimidine **6b** crystals was done at room temperature, collection from imidazole data dicarbonitrile 9a was performed under liquid nitrogen (150 K) using Oxford cryosystems (United Kingdom). The crystal data collection was carried out using Crystalclear (Rigaku, Japan), and processing was done data bv CrystalStructure (Rigaku, Japan) software packages. The structure refinement was performed by SHELXL - 97. All nonhydrogen refined atoms were anisotropically. The hydrogen atoms were placed at calculated positions and refined using a riding model. The molecular graphics and calculation of intermolecular interactions were carried out using Mercury (Version 3.6). The Hirshfeld surface analysis was performed using CrystalExplorer 17.1. (Turner, McKinnon, Wolff, Grimwood, Spackman, et al., 2017).

4.3 General procedure for the synthesis of 5-alkyl-3-(4-nitrophenyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidine-7-carbonitriles **6a,b** 

Triazole 5 (1.00 mmol) was refluxed in a mixture of the excess of  $RC(OEt)_3$  (R = H or C<sub>2</sub>H<sub>5</sub>) and DMF: dioxane 1:1 (1.00 mL) for six hours. The reaction mixture was filtered while hot and cooled to room temperature, the products were precipitated out, and they were then filtered off and recrystallised from hot ethanol.

3-(4-Nitrophenyl)-3*H*-[1,2,3]triazolo[4,5*d*]pyrimidine-7-carbonitrile **6a** 

Colourless crystals (68%), mp: 164-168 °C;  $v_{max}$  (KBr)/cm<sup>-1</sup> 3120, 2230, 1670, 1520, 1430, 1400, 1200, 1180, 845, 680, 640; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 600 MHz):  $\delta$ 7.94 (d, 2H, J = 8.0 Hz, ArH), 8.39 (d, 2H, J = 8.0 Hz, ArH), 9.41 (s, 1H, CH);<sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  116.6, 124.6, 125.4, 131.4, 132.1, 134.5, 135.3, 146.8, 152.9; *m*/*z* (EI) 267 (M<sup>+</sup>); *m*/*z* (EI) 267.0504 (M<sup>+</sup>, C<sub>11</sub>H<sub>5</sub>N<sub>7</sub>O<sub>2</sub> requires 267.0505).

5-Ethyl-3-(4-nitrophenyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidine-7carbonitrile **6b** 

Off-white crystals (71%), mp: 171-174 °C;  $v_{max}$  (KBr)/cm<sup>-1</sup> 3100, 2225, 1615, 1540, 1520, 1410, 1390, 1210, 1190, 1100, 945, 840, 800, 760; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 600 MHz):  $\delta$  1.38 (t, 3H, J = 7.2 Hz, CH<sub>2</sub>CH<sub>3</sub>), 2.94 (q, 2H, J = 7.2 Hz, <u>CH<sub>2</sub>CH<sub>3</sub></u>), 7.91 (d, 2H, J = 8.2 Hz, ArH), 8.41 (d, 2H, J = 8.2, ArH); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  12.9, 32.1, 115.8, 124.9, 122.9, 131.8, 136.2, 137.7, 147.3, 153.6; m/z (EI) 295 (M<sup>+</sup>); m/z (EI) 295.0818 (M<sup>+</sup>, C<sub>13</sub>H<sub>9</sub>N<sub>7</sub>O<sub>2</sub> requires 295.0818).

Synthesis of 3-Amino-3-((*Z*)-2-cyano-2-phenylvinylamino)maleonitrile **8** 

A mixture of phenyl 3-oxopropanenitrile 7 (1.00 mmol), DAMN 2 (1.00 mmol) in CH<sub>3</sub>CO<sub>2</sub>H (10.00 mL was stirred at room temperature for 24 hrs. The green shiny powder formed was filtered off and was used without any further purification. (80%), mp: 207-210 °C decomp.;  $v_{max}$ (KBr)/cm<sup>-1</sup> 3419, 3333, 3270, 3218, 3057, 3025, 2924, 2222, 2208, 1652, 1626, 1602, 1470, 1443, 1376, 1345, 1319, 1286, 1264, 1240, 1193, 1159, 1076, 999; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz):  $\delta$  7.14 (m, 1H, ArH), 7.29 (m, 6H, 4 ArH, 2H, NH<sub>2</sub>), 7.48 (d, 1H, *J* = 10 Hz, CH), 8.65 (d, 1H, *J* = 10 Hz, NH); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  83.97, 93.57, 114.26, 116.90, 117.60, 123.71, 123.92, 126.13, 128.13, 128.99, 133.81, 144.68 m/z (EI) 235 (M<sup>+</sup>) 100%; elemental analysis for C<sub>13</sub>H<sub>9</sub>N<sub>5</sub>: C 66.38, H 3.83, N 29.79. Found: C 66.68, H 3.68, N 29.85%.

4.4 General Procedure for the Synthesis of (*Z*)-1-(2-cyano-2-phenylvinyl)-2-alkyl-1*H*-imidazole-4,5-dicarbonitriles **9a**,**b** 

3-Amino-3-((Z)-2-cyano-2-phenylvinyl-

amino) maleonitrile **8** (1.00 mmol) was refluxed in excess of RC(OEt)<sub>3</sub> R = H or C<sub>2</sub>H<sub>5</sub> and DMF: dioxane 1:1 (1.00 mL) for six hours. The reaction mixture was filtered while hot and cooled to room temperature, the products were precipitated out, and they were then filtered off and recrystallised from hot DCM.

(Z)-1-(2-Cyano-2-phenylvinyl)-1*H*-imidazole-4,5-dicarbonitrile **9a** 

Colourless crystals (67%), mp: 151-153 °C;  $v_{max}$  (KBr)/cm<sup>-1</sup> 3144, 3069, 3003, 2242, 2201, 1737, 1634, 1606, 1542, 1464, 1391, 1375, 1338, 1302, 1258, 1220, 1161, 1144, 1081, 1046, 1001, 918, 874, 768; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz): 7.54 (m, 3H, ArH), 7.72 (m, 2 H, ArH), 8.43 (s, 1H, CH), 8.89 (s, 1H, CH),  $\delta$  <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  94.3, 113.9, 115.2, 118.4, 122.8, 123.7, 125.1, 126.6, 129.0, 133.2, 134.5, 147.3 , m/z (EI) 245 (M<sup>+</sup>) 47%, 244, 100%; m/z (EI) 245.0701 (M<sup>+</sup>, C<sub>14</sub>H<sub>7</sub>N<sub>5</sub> requires 245.0701).

(*Z*)-1-(2-Cyano-2-phenylvinyl)-2-ethyl-1*H*-imidazole-4,5-dicarbonitrile **9b** 

Off-white crystals (65%), mp: 157-159 °C;  $v_{max}$  (KBr)/cm<sup>-1</sup> 3076, 2943, 2235, 2220, 2218, 1649, 1527, 1419, 1302, 1231, 1029, 1005, 941; <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, 400 MHz):  $\delta$  1.21 (t, 3H, J = 7.2 Hz, CH<sub>2</sub>CH<sub>3</sub>), 2.84 (q, 2H, J = 7.2 Hz, <u>CH<sub>2</sub>CH<sub>3</sub></u>), 7.57 (m, 3H, ArH), 7.77 (m, 2H, ArH), 8.40 (s, 1H, CH); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>):  $\delta$  11.82, 21.56, 97.2, 114.5, 116.4, 117.9, 122.5, 123.1, 125.8, 127.7, 128.4, 134.0, 136.2, 146.3; m/z (EI) 273 (M<sup>+</sup>) 84 %, 258, 100 %; m/z (EI) 273.1013 (M<sup>+</sup>, C<sub>16</sub>H<sub>11</sub>N<sub>5</sub> requires 273.1014).

## ACKNOWLEDGEMENTS

Facilities provided by the RSPU facilities through projects GS 03/08, GS 01/01, GS 01/03, and GS 01/05 at Kuwait University are gratefully acknowledged.

-14-

# Appendix A: Supplementary Material

Single-crystal data for compounds triazolopyrimidine 6b (CCDC 993548) and (CCDC imidazole dicarbonitrile 9a 2004526) have been deposited in Cambridge Crystallographic Data Centre. Supplementary data associated with this article be found can at http://www.ccdc.cam.ac.uk/conts/retrievin g.html.

## References

Al-Azmi, A.; Booth, B. L.; Carpenter, R. A.; Carvalho, A.; Marrelec, E. *et al.* (2001). Facile synthesis of 6-cyano-9substituted-9*H*-purines and their ring expansion to 8-(arylamino)-4-imino-3methylpyrimidino[5,4-d]pyrimidines.

Journal of the Chemical Society, Perkin Transactions **1:** 2532-2537, http://doi.org/10.1039/B106539B.

Al-Azmi, A.; Elassar, A.-Z. A. & Booth, B. L. (2003). The chemistry of diaminomaleonitrile and its utility in heterocyclic synthesis. Tetrahedron, **59**: 2749-2763, doi:10.1016/S0040-4020(03)00153-4.

Al-Azmi, A. (2005). Novel 6-substituted Pyrimidines and Pyrimido[5,4*d*]pyrimidines from (2-acetamido-1,2dicyanovinyl)Ammonium Chloride. Journal of Chemical Research: 530-534, <u>https://doi.org/10.3184/030823405774663</u> 200.

Al-Azmi, A. & Kumari, K. A. (2009). Reactions of 9-aryl-6-cyanopurines with primary amines. Heterocycles, **78**: 2245-2262, doi:10.3987/COM-09-11713.

**Al-Azmi, A. & Kalarikkal, A. K. (2013).** Synthesis of 1,4,5-trisubstituted-1,2,3triazoles via coupling reaction of diaminomaleonitrile with aromatic diazonium salts. Tetrahedron, **69:** 1112211129,

http://doi.org/10.1016/j.tet.2013.11.003.

Al-Azmi, A. (2015). Recent Developments in the Chemistry of Diaminomaleonitrile. Current Organic Synthesis, 12: 110-135, http://doi.org/10.2174/1570179412666141 226190750

Al-Azmi, A. & Kalarikkal, A. K. (2017). Versus Pyrazolo[1,5-Pvrazoles Pyridones *a*]pyrimidines and Versus Enamines: **Re-actions** of 2-Aryl-3oxopropanenitrile with Nitrogen and Carbonyl Compounds. Current Organic Synthesis, 14: 1198-1213, http://doi.org/10.2174/1570179414666171 004162558.

Al-Azmi, A. (2020). DFT Study on Two Plausible Mechanistic Routes to Pyrazolo[3,4-*d*]pyrimidine-4-Amines from Pyrazoloformimidate. Current Organic Chemistry, 24: 216-229, doi:10.2174/138527282466620020312245 0.

Al-Azmi, A. & Mahmoud, H. (2020). Facile Synthesis and Antimicrobial Activities of Novel 1,4-Bis(3,5-dialkyl-4H-1,2,4-triazol-4-yl)benzene and 5-Aryltriaz-1-en-1-yl-1-phenyl-1H-pyrazole-4carbonitrile Derivatives. ACS Omega, 5: 10160-10166,

doi.org/10.1021/acsomega.0c01001.

Ali, I.; Lone, M. N. & Aboul-Enein, H. Y. (2017). Imidazoles as potential anticancer agents. Med. Chem. Comm., 8: 1742-1773,

http://doi.org/10.1039/C7MD00067G.

Alves, M. J.; Booth, B. L. & Proenca, M. F. J. R. P. (1990). Synthesis of 5-amino-4-(cyanoformimidoyl)-1*H*-imidazole: a reactive intermediate for the synthesis of 6carbamoyl-1,2-dihydropurines and 6carbamoylpurines. Journal of the Chemical Society, Perkin Transactions 1: 1705-1712, http://doi.org/10.1039/P19900001705. Booth, B. L.; Dias, A. M. & Proenca, M. F. (1992). Synthesis of 9-hydroxyalkyl-substituted purines from the corresponding 4-(C-cyanoformimidoyl)imidazole-5-

amines. Journal of the Chemical Society, Perkin Transactions 1: 2119-2126, http://doi.org/10.1039/P19920002119.

El-Sayed, W. A.; Ali, O. M.; Faheem, M. S.; Zied, I. F. & Abdel-Rahman, A. A.-H. (2012). Synthesis and Antimicrobial Activity of New 1,2,3-Triazolopyrimidine Derivatives and Their Glycoside and Acyclic Nucleoside Analogs. *Journal of Heterocyclic Chemistry*, **49**: 607-612, http://doi.org/10.1002/jhet.832.

Hassan, G. S.; El-Sherbeny, M. A.; El-Ashmawy, M. B.; Baymoi, S. M. *et al.* (2017). Synthesis and antitumor testing of certain new fused triazolopyrimidine and triazoloquinazoline derivatives. Arabian Journal of Chemistry, **10**: S1345-S1355, http://doi.org/10.1016/j.arabjc.2013.04.002

Hlouskova, Z. & Bures, F. (2017). Synthesis and properties of push-pull imidazole derivatives with application as photoredox catalysts. Organic Chemistry, 330-342,

http://doi.org/10.24820/ark.5550190.p010. 071.

Johnson, S. J. (1991). 1-Alkylation of 4, 5-dicyanoimidazole by ortho esters. Synthesis (Stuttgart): 75-78, doi:10.1055/s-1991-26384.

Mckinnon, J. J.; Spackman, M. A. & Mitchell, A. S. (2004). Novel tools for visualizing and exploring intermolecular interactions in molecular crystals. Acta Crystallographica Section B: Structural Science, 60: 627-668 http://doi.org/10.1107/S010876810402030 0

Mckinnon, J. J.; Jayatilaka, D. & Spackman, M. A. (2007). Towards

quantitative analysis of intermolecular interactions with Hirshfeld surfaces. Chemical Communications: **3814-3816**, <u>http://doi.org/10.1039/B704980C</u>.

Nicolai, E.; Cure, G.; Goyard, J.; Kirchner, M.; Teulon, J.-M. *et al.* (1994). Synthesis and SAR Studies of Novel Triazolopyrimidine Derivatives as Potent, Orally Active Angiotensin II Receptor Antagonists. Journal of Medicinal Chemistry, **37**: 2371-2386, http://doi.org/10.1021/jm00041a016.

Plaquet, A.; Champagne, B.; Kulhanek, J.; Bures, F.; Bogdan, E. *et al.* (2011). Effects of the Nature and Length of the π-Conjugated Bridge on the Second-Order Nonlinear Optical Responses of Push-Pull Molecules Including 4,5-Dicyanoimidazole and Their Protonated Forms. Chem. Phys. Chem., **12**: 3245-3252, http://doi.org/10.1002/cphc.201100299.

Spackman, M. A. & Jayatilaka, D. (2009). Hirshfeld surface analysis. Cryst. Eng. Comm., 11: 19-32, <u>http://doi.org/10.1039/B818330A</u>.

Turner, M. J.; McKinnon, J. J.; Wolff, S. K.; Grimwood, D. J.; Spackman, P. R. *et al.* (2017). CrystalExplorer 17, University of Western Australia. <u>http://hirshfeldsurface.ne</u>

**Woodward, D. W. (1950).** 4, 5imidazoledicarbonitrile and method of preparation. US Patent No. 2534331.

**Yildirim, I.; Akcamur, Y.; Saripinar, E.; Kollenz, G. (2002).** On the synthesis of some N-Alkyl Pyrimidine derivatives and determination of their structures. Kuwait Journal of Science and Engineering, **29** (2): 57-65.

| Submitted | : 13/05/2020              |
|-----------|---------------------------|
| Revised   | :07/09/2020               |
| Accepted  | : 13/09/2020              |
| DOI       | : 10.48129/kjs.v48i2.9948 |

-16-